Jump to content

Platelet transfusion ABO-nonidentical


Recommended Posts

When nonavailable ABO-identical platelets. What to transfuse?

Patients of group A
1st choice: AB (incompatibility major) 
2nd choice: B (incompatibility major) 


1st choice: O (incompatibility minor)

Link to comment
Share on other sites

This is a controversial subject. Firstly, ABO identical is by the most effective and safest. ABO mismatched platelets are associated in randomized trials with a 2-5 fold increase in refractoriness to transfusion, with is in itself associated with early mortality.  ABO mismatched platelets in observational studies are associated with increases in febrile transfusion reactions, allergic transfusion reactions, increased bleeding and mortality.

Is a single transfusion likely to be lethal? Probably not, but the blithe use of any old ABO type for multiple transfusions is highly likely to cause morbidity and mortality.  In a pinch, when the ABO is not known or ABO identical aren't available, washed or plasma reduced group O platelets are probably safest.  If not available, group A is probably safest.  My last choice in all instances would be plasma replete group O, because there is a tiny but real risk of a fatal ABO hemolytic reaction due to the 250 ml of incompatible plasma.  Incompatible antigen is probably less risky, hence the recommendation of group A platelets. Group A plasma has anti-B, which is the least dangerous of the two isoagglutinins in every respect.  


Is It Time to Reconsider the Concepts of "Universal Donor" and "ABO Compatible" Transfusions?

Refaai MA, Cahill C, Masel D, Schmidt AE, Heal JM, Kirkley SA, Blumberg N.

Anesth Analg. 2018 Jun;126(6):2135-2138. doi: 10.1213/ANE.0000000000002600.


Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Similar Content

    • By Neil Blumberg
      Research letter in NEJM describes our findings.  https://www.nejm.org/doi/full/10.1056/NEJMc2034764?fbclid=IwAR1BQRvpaHBAMDaHxCPY07xBjPQHlIHoJCOmpjoT_pBNvQsV7pzzDVdLYaY
      Table 1. HLA-Matched Platelets as a Percentage of All Platelet Transfusions, According to the Initiation of Other Protocols.*
      Protocol and Timing of Initiation No. of Years HLA-Matched Platelets Difference from Previous Period (95% CI)     median % (IQR) percentage points No leukoreduction and no ABO matching (1985–1990) 6 12.5 (4.2–13.7) NA Leukoreduction and ABO matching for patients with leukemia and MDS (1991–1999)† 5 2.9 (2.0–3.6) 9.6 (9.4–9.8) Universal leukoreduction (2001–2004) 4 1.4 (1.1–2.0) 1.5 (1.4–1.6) Universal ABO matching (2005–2015) 11 0.4 (0.2–0.8) 1.0 (1.0–1.1) Pathogen reduction of platelets (2016–2019)‡ 4 1.7 (0.8–1.8) ND  
      The practical fact is that this can only be implemented by medical technologists, not physicians, and this is a daunting prospect.  But the reality is that ABO mismatched platelet transfusions probably exacerbate rather than prevent bleeding, so waiting for ABO identical is likely better than just transfusing whatever is available.  This is going to require a major change of approach because the (incorrect) dogma, based upon no data, is that ABO doesn't matter for platelets.
      I understand why many people's instant reaction is this is not feasible. But it is once technical experts in your transfusion service figure out how to implement it gradually. In our randomized trial back in 1993 (see ref below), the ABO identical group only required <50% the number of platelet transfusions (every other day instead of every day on average) compared with the usual first in, first out regardless of ABO type group. ABO mismatched transfusions create a hostile environment with gigantic immune complexes that compromise subsequent transfusion that may be ABO identical. Avoiding this is key.
      Our suggestion is to start gradually. Pick new previously untransfused patients with aplastic anemia and good prognosis AML (young, favorable or normal cytogenetics), groups O or A, and start with them. Eminently doable since your platelet supply is 45% O and 40% A, just like your patients, on average. Get the hang of doing this and prioritizing ABO for at least some patients. Once you get this in place, extending it to other patients and eventually all patients can happen. We use washed O or A platelets and red cells for group B and AB recipients when we don't have group B or AB platelets. No increase in bleeding and fewer transfusion reactions, lung injury and congestive heart failure (what we call TRALI and TACO).
      In the end, you have more surviving patients and fewer headaches and transfuse many fewer platelets per patient and essentially no HLA if you can get your referring hospitals to stop our current standard harmful practices. Godspeed. Heal JM, Rowe JM, McMican A, Masel D, Finke C, Blumberg N. The role of ABO matching in platelet transfusion. Eur J Haematol. 1993 Feb;50(2):110-7. doi: 10.1111/j.1600-0609.1993.tb00150.x. PMID: 8440356.
      Happy to have discussions or visitors so our technical experts can show you how it is feasible.
    • By Sherie Bruns
      Do anyone  require a current sample and a separate blood bank armband for transfusion of platelets?  My current Blood bank only requires two historic ABO/Rh tests before transfusing platelets.  I am wondering if this meets the CAP standard for prevention of misidentification, TRM30550.
  • Advertisement

  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.